iBio reports positive financial results for Q3, raises $6.2 million, and makes progress in pipeline

From GlobeNewswire.: 2025-05-02 08:00:00

iBio, Inc. (Nasdaq:IBIO) reported financial results for Q3 ending March 31, 2025. They raised $6.2 million through a warrant-inducement equity raise and began trading on the Nasdaq Stock Exchange under the ticker symbol “IBIO.” The company made significant strides in its pipeline, with promising data for IBIO-600 and an in-licensed Activin E antibody.

In Q3 2025, R&D expenses were $1.9 million, G&A expenses were $3.0 million, and net loss was $4.9 million. Cash, cash equivalents, and restricted cash were $5.2 million as of March 31, 2025, increasing to approximately $10.5 million by May 1, 2025, after the equity raise.

iBio is a biotech company leveraging AI for biopharmaceuticals. They aim to develop treatments for various diseases. The company’s progress and financial results position them for continued growth and a regulatory submission of IBIO-600 in 2026. For more information, visit www.ibioinc.com.



Read more at GlobeNewswire.:: iBio Reports Fiscal Third Quarter 2025 Financial Results